A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Zepbound brought in $2.3 billion in U.S. sales during this year’s first quarter, making it one of drugmaker Eli Lilly’s best sellers. Novo Nordisk says Wegovy has about 200,000 weekly ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 were still taking them 12 months later. News. Today's news; US; ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Most Innovative Companies Super-Early-Rate Deadline: This Friday, July 25.

Zepbound’s results were relatively unchanged year over year, though the number of U.S. patients starting on the medication in 2023 was limited since it did not launch until November of that year.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those ...